Combination Therapy of Interleukin-2 and Sorafenib Improves Survival Benefits and Prevents Spontaneous Pulmonary Metastasis in Murine Renal Cell Carcinoma Models

被引：6
|
作者：
Amagai, Yosuke [1 ]
Matsumoto, Mitsunobu [1 ]
Hojo, Kanji [1 ]
Iguchi, Motofumi [1 ]
Wada, Tooru [1 ]
Tanaka, Hidekazu [1 ]
Ide, Nobuyuki [1 ]
Kato, Akira [1 ]
Shichijo, Michitaka [1 ]
Abe, Kenji [1 ]
机构：
[1] Shionogi & Co Ltd, Sci Coordinat & Promot, Discovery Res Labs, Tokyo 1500002, Japan
来源：
JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 40卷 / 06期
关键词：
IL-2; sorgfenib; combination therapy; renal cell carcinoma; pulmonaty metastasis; RECOMBINANT HUMAN INTERLEUKIN-2; TUMOR PROGRESSION; ANGIOGENESIS; INTERFERON;
D O I：
10.1093/jjco/hyp200
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objective: The objective of this study was to evaluate the benefits of combination therapy consisting of recombinant human interleukin-2 and sorafenib for survival efficacy and the suppression of metastasis in murine renal cell carcinoma models. Methods: Lung-metastasized renal cell carcinoma mice were treated with various combinations of recombinant human interleukin-2 and sorafenib. Tumor growth was observed using a bioluminescence imaging system. Next, the nephrectomized renal cell carcinoma mice were administered various combinations of recombinant human interleukin-2 and sorafenib, followed by a lung resection in order to examine lung metastasis by bioluminescence imaging. Results: The increased life-span ratio in mice receiving combination therapy was 1.45, whereas that in mice treated with sorafenib or recombinant human interleukin-2 alone therapy was 1.28 and 1.07, respectively. The concomitant administration of recombinant human interleukin-2 and sorafenib had a metastasis-inhibitory effect, whereas the other treatments failed. Conclusions: These findings indicate that combination therapy of recombinant human interleukin-2 and sorafenib may offer better outcomes than either monotherapy with recombinant human interleukin-2 or sorafenib with respect to survival benefits and the prevention of pulmonary metastasis in renal cell carcinoma patients.
引用
收藏
页码：503 / 507
页数：5
相关论文
共 50 条
  • [1] Combination treatment with interleukin-2 and interleukin-12 for murine renal cell carcinoma
    Onishi T.
    Ohishi Y.
    Goto H.
    Imagawa K.-I.
    Ohmoto Y.
    Wada K.
    [J]. International Journal of Clinical Oncology, 1999, 4 (6) : 364 - 371
  • [2] COMBINATION THERAPY WITH ADRIAMYCIN AND INTERLEUKIN-2 AUGMENTS IMMUNITY AGAINST MURINE RENAL-CELL CARCINOMA
    GAUTAM, SC
    CHIKKALA, NF
    GANAPATHI, R
    HAMILTON, TA
    [J]. CANCER RESEARCH, 1991, 51 (22) : 6133 - 6137
  • [3] EFFECT OF COMBINATION TREATMENT WITH INTERLEUKIN-2 AND RADIATION FOR MURINE RENAL-CELL CARCINOMA
    ONISHI, T
    MACHIDA, T
    IIZUKA, N
    SHIRAKAWA, H
    HATANO, T
    MAKINO, H
    SAWADA, T
    [J]. CANCER JOURNAL - FRANCE, 1992, 5 (04): : 230 - 234
  • [4] RADIOFREQUENCY ABLATION COMBINED WITH INTERLEUKIN-2 PREVENTS METASTASIS FORMATION IN MOUSE RENAL CELL CARCINOMA
    Kroeze, Stephanie G. C.
    Nijkamp, Maarten W.
    Roodhart, Jeanine M. L.
    de Gast, Gijsbert C.
    Bosch, J. L. H. Ruud
    Jans, Judith J. M.
    [J]. JOURNAL OF UROLOGY, 2011, 185 (04): : E155 - E155
  • [5] Symptomatic neurological epidural metastasis with interleukin-2 therapy in metastatic renal cell carcinoma
    Trufflandier, N
    Gille, O
    Palussière, J
    Prié, L
    Pointillart, V
    Ravaud, A
    [J]. TUMORI, 2002, 88 (04) : 338 - 340
  • [6] Successful Outcomes Using Combination Therapy of Interleukin-2 and Interferon-α for Renal Cell Carcinoma Patients with Lung Metastasis
    Akaza, Hideyuki
    Kawai, Koji
    Tsukamoto, Taiji
    Fujioka, Tomoaki
    Tomita, Yoshihiko
    Kitamura, Tadaichi
    Ozono, Seiichiro
    Miki, Tsuneharu
    Naito, Seiji
    Zembutsu, Hitoshi
    Nakamura, Yusuke
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (07) : 684 - 689
  • [7] Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
    G Procopio
    E Verzoni
    S Bracarda
    S Ricci
    C Sacco
    L Ridolfi
    C Porta
    R Miceli
    N Zilembo
    E Bajetta
    [J]. British Journal of Cancer, 2011, 104 : 1256 - 1261
  • [8] Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
    Procopio, G.
    Verzoni, E.
    Bracarda, S.
    Ricci, S.
    Sacco, C.
    Ridolfi, L.
    Porta, C.
    Miceli, R.
    Zilembo, N.
    Bajetta, E.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 104 (08) : 1256 - 1261
  • [9] Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis
    Guma, Sergei R.
    Lee, Dean A.
    Ling, Yu
    Gordon, Nancy
    Kleinerman, Eugenie S.
    [J]. PEDIATRIC BLOOD & CANCER, 2014, 61 (08) : 1362 - 1368
  • [10] Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: Six years of experience
    Huland, E
    Heinzer, H
    Mir, TS
    Huland, H
    [J]. CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1997, 3 : S98 - S105
12345